Gene- and cell-based therapies for cardiovascular diseases: Current status and future directions

European Heart Journal, Supplement

Volumn 6, Issue E, 2004, Pages

  Melo, L G ^a,b   Gnecchi, M ^a   Pachori, A S ^a   Wang, K ^b   Dzau, V J ^a  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b QUEEN S UNIVERSITY   (Canada)

Author keywords

Bone marrow; Cardiac progenitors; Cellular cardiomyoplasty; Coronary artery disease; Endothelial progenitor cells; Heme oxygenase; Protective gene therapy

Indexed keywords

ADENOVIRUS VECTOR; ANGIOGENIC FACTOR; ANGIOTENSIN; ANTICOAGULANT AGENT; ANTILIPEMIC AGENT; ANTIOXIDANT; ANTISENSE OLIGONUCLEOTIDE; APOLIPOPROTEIN A1; ATRIAL NATRIURETIC FACTOR; COPPER ZINC SUPEROXIDE DISMUTASE; CYTOKINE; DRUG CARRIER; ENDOTHELIAL NITRIC OXIDE SYNTHASE; EXTRACELLULAR SUPEROXIDE DISMUTASE; FIBROBLAST GROWTH FACTOR; FIBROBLAST GROWTH FACTOR 4; GLUTATHIONE PEROXIDASE; GRANULOCYTE COLONY STIMULATING FACTOR; GREEN FLUORESCENT PROTEIN; HEAT SHOCK PROTEIN; HEME OXYGENASE 1; INDUCIBLE NITRIC OXIDE SYNTHASE; NITRIC OXIDE SYNTHASE; PROTEIN BCL 2; SCATTER FACTOR; SUPEROXIDE DISMUTASE; SYNTHETIC PEPTIDE; TRANSCRIPTION FACTOR E2F1; UNCLASSIFIED DRUG; UNINDEXED DRUG; VASCULOTROPIN; VASCULOTROPIN C;

APOPTOSIS; ARTERY INTIMA PROLIFERATION; ATHEROSCLEROSIS; BLOOD VESSEL INJURY; CARDIOVASCULAR DISEASE; CARDIOVASCULAR SYSTEM; CELL BASED GENE THERAPY; CELL DIFFERENTIATION; CELL TRANSPLANTATION; CLINICAL TRIAL; CONFERENCE PAPER; CYTOLOGY; DRUG DELIVERY SYSTEM; DRUG EFFICACY; DRUG SAFETY; ENDOTHELIUM CELL; GENE TARGETING; GENE THERAPY; GENETIC MANIPULATION; HEART MUSCLE INJURY; HEART MUSCLE ISCHEMIA; HEART PROTECTION; HUMAN; HYPERTENSION; ISCHEMIA; MYOCARDITIS; NONHUMAN; OXIDATIVE STRESS; PHENOTYPE; PRIORITY JOURNAL; SIDE EFFECT; STEM CELL; THROMBOSIS; TISSUE REPAIR; VASCULAR DISEASE; VASCULARIZATION; VIRUS RECOMBINANT;

EID: 4043112624     PISSN: 1520765X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ehjsup.2004.06.001     Document Type: Conference Paper

References (157)

1. Nabel E.G. Cardiovascular disease. New Engl. J. Med. 349:2003;60-72
2. Mah C., Byrne B.J., Flotte T.R. Virus-based gene delivery systems. Clin. Pharmacokin. 41:2002;901-911
3. Monahan P.E., Samulski R.J. AAV vectors: is clinical success on the horizon? Gene Therapy. 7:2000;24-30
4. Niidome T., Huang L. Gene therapy progress and prospects: non-viral vectors. Gene Therapy. 9:2002;1647-1652
5. Sylven C., Sarkar N., Insulander P., et al. Catheter-based transendocardial myocardial gene transfer. J. Interv. Cardiol. 15:2002;7-13
6. Melo L.G., Pachori A.S., Kong D., et al. Gene- and cell-based therapies for heart disease. FASEB J. 18:2004;648-663
7. Herttuala S.Y., Alitalo K. Gene transfer as a tool to induce therapeutic vascular growth. Nat. Med. 9:2003;694-700
8. Melo L.G., Agrawal R., Zhang L., et al. Gene therapy strategy for long term myocardial protection using adeno-associated virus-mediated delivery of heme oxygenase gene. Circulation. 105:2002;602-607
9. Mack C.A., Patel S.A., Schwarz E.A., et al. Biological bypass with the use of adenovirus-mediated transfer of the complementary deoxyribonucleic acid for vascular endothelial growth factor 121 improves myocardial perfusion and function in the ischemic porcine heart. J. Thorac. Cardiovasc. Surg. 115:1998;168-177
10. Morishita R., Sugimoto T., Aoki M., et al. In vivo transfection of cis element decoy against nuclear factor κB binding sites prevents myocardial infarction. Nat. Med. 3:1997;894-899
11. Mann M.J., Dzau V.J. Genetic manipulation of vein grafts. Curr. Opin. Cardiol. 12:1997;522-527
12. Morishita R., Gibbons G.H., Ellison K.E., et al. A gene therapy strategy using a transcription factor decoy of the E2F binding site inhibits smooth muscle proliferation in vivo. Proc. Natl. Acad. Sci. USA. 92:1995;5855-5859
13. Asahara T., Murohara T., Sullivan A., et al. Isolation of putative progenitor endothelial cells for angiogenesis. Science. 275:1997;964-967
14. Masuda H., Asahara T. Post-natal endothelial progenitor cells for neovascularization on tissue regeneration. Cardiovasc. Res. 58:2003;390-398
15. Rafii S., Lyden D. Therapeutic stem and progenitor cell transplantation for organ vascularization and regeneration. Nat. Med. 9:2003;702-712
16. Laham R.J., Simons M., Sellke F. Gene transfer for angiogenesis in coronary artery disease. Ann. Rev. Med. 52:2001;485-502
17. Isner J.M. Myocardial gene therapy. Nature. 415:2002;234-239
18. Robbins P.D., Ghivizzani C. Viral vectors for gene therapy. Pharmacol. Therapy. 80:1998;35-47
19. Cartier R., Reszka R. Utilization of synthetic peptides containing nuclear localization signals for nonviral gene transfer. Gene Ther. 9:2002;157-167
20. Trono D. Lentiviral vectors: turning a deadly foe into a therapeutic agent. Gene Therapy. 7:2000;20-23
21. Hartigan-O'Connor D., Amalfitano A., Chamberlain J.S., et al. Improved production of gutted adenovirus in cells expressing adenovirus preterminal protein and DNA polymerase. J. Virol. 73:1999;7835-7841
22. Chirmule N., Propert K., Magosin S., et al. Immune responses to adenovirus and adeno associated virus in humans. Gene Ther. 6:1999;1574-1583
23. Prentice H., Bishopric N., Hicks M.N., et al. Regulated expression of a foreign gene targeted to the ischaemic myocardium. Cardiovasc. Res. 35:1997;567-574
24. Lin K.F., Chao L., Chao J. Prolonged reduction of high blood pressure with human nitric oxide synthase delivery. Hypertension. 30:1997;307-313
25. Lin K.F., Chao J., Chao L. Atrial natriuretic peptide gene delivery attenuates hypertension, cardiac hypertrophy and renal injury in salt-sensitive rats. Hum. Gene Ther. 9:1998;1429-1438
26. Wang H., Katovich M.J., Gelband C.H., et al. Sustained inhibition of angiotensin I converting enzyme (ACE) expression and long-term antihypertensive action by virally mediated delivery of ACE antisense cDNA. Circ. Res. 85:1999;614-622
27. Kimura B., Mohuczy D., Tang X., et al. Attenuation of hypertension and heart hypertrophy by adeno-associated virus delivering angiotensin antisense. Hypertension. 37:2001;376-380
28. Braun-Dullaeus R.D., Mann M.J., Dzau V.J. Cell cycle progression. New therapeutic target for vascular proliferative disease. Circulation. 98:1998;82-89
29. Chang M.W., Barr E., Lu M.M., et al. Adenovirus-mediated over-expression of the cyclin/cyclin dependent kinase inhibitor, p21 inhibits vascular smooth muscle proliferation and neointima formation in the rat carotid artery model of balloon angioplasty. J. Clin. Invest. 96:1995;2260-2268
30. Morishita R., Gibbons G.H., Ellison K.E., et al. Single intraluminal delivery of antisense cdc2 kinase and proliferating cell nuclear antigen oligonucleotides results in chronic inhibition of neointimal hyperplasia. Proc. Natl. Acad. Sci. USA. 90:1993;8474-8478
31. Kim A.Y., Wallinsky P.L., Kolodgie F.D. Early loss of thrombomodulin expresson impairs vein graft thromboresistance: implications for vein graft resistance. Circ. Res. 90:2002;205-212
32. Waugh J.M., Yuksel E., Li J., et al. Local overexpression of thrombomodulin for in vivo prevention of arterial thrombosis in a rabbit model. Circ. Res. 84:1999;84-92
33. Dicheck D.A., Anderson J., Kelly A.B. Enhanced antithrombotic effects of endothelial cells expressing recombinant plasminogen activators transduced with retroviral vectors. Circulation. 93:1996;301-309
34. Zoldhelyi P., McNatt J., Shelat H.S., et al. Thromboresistance of balloon-injured porcine carotid arteries after local gene transfer of human tissue factor pathway inhibitor. Circulation. 101:2000;289-295
35. Griese D.P., Ehsan A., Melo L.G., et al. Isolation and transplantation of autologous circulating endothelial cells into denuded vessels and prosthetic grafts: implications for cell-based vascular therapy. Circulation. 108:2003;2710-2715
36. Kaushal S., Amiel G.E., Guleserian K.J., et al. Functional small-diameter neovessels created using endothelial progenitor cells expanded ex vivo. Nat. Med. 7:2001;1035-1040
37. Li Q., Bolli R., Qiu Y., et al. Gene therapy with extracellular superoxide dismutase protects conscious rabbits against myocardial infarction. Circulation. 103:2001;1893-1898
38. Woo Y.Z., Zhang J.C., Vijayasarathy C., et al. Recombinant adenovirus-mediated cardiac gene transfer of superoxide dismutase and catalase attenuates postischaemic contractile dysfunction. Circulation. 98(Suppl.):1998;II255-II260
39. Zhu H.L., Stewart A.S., Taylor M.D. Blocking free radical production via adenoviral gene transfer decreases cardiac ischaemia-reperfusion injury. Mol. Therapy. 2:2000;470-475
40. Chatterjee S., Stewart A.S., Bish L.T., et al. Viral gene transfer of the antiapoptotic factor Bcl-2 protects against chronic ischaemic heart failure. Circulation. 106(Suppl.):2002;I212-I217
41. Fujio Y., Nguyen T., Wencker D., et al. Akt promotes survival of cardiomyocytes in vitro and protects against ischaemia-reperfusion injury in mouse heart. Circulation. 101:2000;660-667
42. Matsui T., Tao J., del Monte F., et al. Akt activation preserves cardiac function and prevents injury after transient cardiac ischemia in vivo. Circulation. 104:2001;330-335
43. Poston R.S., Mann M.J., Hoyt E.G., et al. Antisense oligodeoxynucleotides prevent acute cardiac allograft rejection via a novel, non-toxic, highly efficient transfection method. Transplantation. 68:1999;825-832
44. Feldman L.J., Isner J.M. Gene therapy for vulnerable plaque. J. Am. Coll. Cardiol. 26:1995;826-833
45. 121 cDNA to individuals with clinically significant severe coronary artery disease. Circulation. 100:1999;468-474
46. Symes J.F., Losordo D.W., Vale P.R., et al. Gene therapy with vascular endothelial growth factor for inoperable coronary artery disease. Ann. Thor. Surg. 68:1999;830-837
47. Giordano F.J., Ping P., McKirnan M.D., et al. Intracoronary gene transfer of fibroblast growth factor-5 increases blood flow and contractile function in ischemic region of the heart. Nat. Med. 2:1996;534-539
48. Ueno H., Li J.J., Masuda S., et al. Adenovirus-mediated expression of the secreted form of basic fibroblast growth factor (FGF-2) induces cellular proliferation and angiogenesis in vivo. Arterioscler. Thromb. Vasc. Biol. 17:1997;2453-2460
49. Tabata H., Silver M., Isner J.M. Arterial gene transfer of acidic fibroblast growth factor for therapeutic angiogenesis in vivo: critical role of secretion signal in use of naked DNA. Cardiovasc. Res. 25:1997;470-474
50. Ueda H., Sawa Y., Matsumoto K., et al. Gene transfection of hepatocyte growth factor attenuates reperfusion injury in the heart. Ann. Thorac. Surg. 67:1999;1726-1731
51. Taylor D.A., Atkins B.Z., Hungspreugs P., et al. Regenerating functional myocardium improves performance after skeletal myoblast transplantation. Nat. Med. 4:1998;929-933
52. Menasché P., Hagege A.A., Scorsin M., et al. Myoblast transplantation for heart failure. Lancet. 357:2001;279-280
53. Leor J., Patterson M., Quinones M.J., et al. Transplantation of fetal myocardial tissue into the infarcted myocardium of rat. A potential method for repair of infarcted myocardium. Circulation. 94(Suppl. II):1996;II-332-II-336
54. Reinecke H., Zhang M., Bartosek T., et al. Survival, integration, and differentiation of cardiomyocyte grafts: a study in normal and injured rat hearts. Circulation. 100:1999;193-202
55. Orlic D., Kajstura J., Chimenti S., et al. Bone marrow cells regenerate infarcted myocardium. Nature. 410:2001;701-705
56. Tomita S., Li R.K., Weisel R.D., et al. Autologous transplantation of bone marrow cells improves damaged heart function. Circulation. 100(Suppl.):1999;II-247-II-256
57. Cines D.B., Pollak E.S., Buck C.A. Endothelial cells in physiology and in the pathophysiology of vascular disorders. Blood. 91:1998;3527-3561
58. Quyyumi A.A. Endothelial function in health and disease: new insights into the genesis of cardiovascular disease. Am. J. Med. 105(1A):1998;32S-39S
59. Bennet M.R., O'Sullivan M.O. Mechanisms of angioplasty and stent restenosis: implications for design of rational therapy. Pharmacol. Therapy. 91:2001;149-166
60. Schwartz R.S. Pathophysiology of restenosis: interaction of thrombosis, hyperplasia and/or remodeling. Am. J. Cardiol. 81(7A):1998;14E-17E
61. Kibbe M.R., Billiar T.R., Tzeng E. Gene therapy for restenosis. Circ. Res. 86:2000;829-833
62. Tang X., Mohuczy D., Zhang C.Y., et al. Intravenous angiotensinogen antisense in AAV-based vector decreases hypertension. Am. J. Physiol. 277:1999;H2392-H2399
63. Kong D., Zhang L., Gnecchi M., et al. Cytokine-mobilized bone marrow cells re-endothelialize injured blood vessels and inhibit neointimal formation. [Abstract] Mol. Therapy. 7:2003;S226
64. Cho H.-.J., Kim H.-.S., Lee M.-.M., et al. Mobilized endothelial progenitor cells by granulocyte-macrophage colony stimulating factor accelerate reendothelialization and reduce vascular inflammation after intravascular radiation. Circulation. 108:2003;2918-2925
65. Tangirala R.K., Tsukamoto K., Chun S.H., et al. Regression of atherosclerosis induced by liver-directed gene transfer of apolipoprotein A-1 in mice. Circulation. 100:1999;1816-1822
66. Inoue S., Egashira K., Ni W., et al. Anti-monocyte chemoattractant protein-1 gene therapy limits progression and destabilization of established atherosclerosis in apolipoprotein E-knockout mice. Circulation. 106:2002;2700-2706
67. von der Leyen H.E., Dzau V.J. Therapeutic potential of nitric oxide synthase gene manipulation. Circulation. 103:2001;2760-2765
68. Gewaltig M.T., Kojda G. Vasoprotection by nitric oxide: mechanisms and therapeutic potential. Cardiovasc. Res. 55:2002;250-260
69. Shears III L.L., Kawaharada N., Tzeng E., et al. Inducible nitric oxide synthase suppresses the development of allograft atherosclerosis. J. Clin. Invest. 100:1997;2035-2042
70. Qian H., Neplioueva V., Shetty G.A., et al. Nitric oxide synthase gene therapy rapidly reduces molecule expression and inflammatory cell infiltration in carotid artery of cholesterol-fed rabbits. Circulation. 99:1999;2979-2982
71. Juan S.H., Lee T.S., Tseng K.W., et al. Adenovirus-mediated heme oxygenase-1 gene transfer inhibits the development of atherosclerosis in apolipoprotein E-deficient mice. Circulation. 104:2001;1519-1525
72. Zanetti M., Sato J., Jost C.J., et al. Gene transfer of manganese superoxide dismutase reverses vascular dysfunction in the absence but not in the presence of atherosclerotic plaque. Hum. Gene Ther. 12:2001;1407-1416
73. Grossman M., Rader D.J., Muller D.W., et al. A pilot study of ex vivo gene therapy for homozygous familial hypercholesterolaemia. Nat. Med. 1:1995;1148-1154
74. Dzau V.J., Braun-Dullaeus R.C., Sedding D.G. Vascular proliferation and atherosclerosis: new perspectives and therapeutic strategies. Nat. Med. 8:2002;1249-1256
75. Von der Leyen H.E., Gibbons G.H., Morishita R., et al. Gene therapy inhibiting neointimal vascular lesion: in vivo transfer of endothelial cell nitric oxide synthase gene. Proc. Natl. Acad. Sci. USA. 92:1995;1137-1141
76. Tzeng E., Shears L.L., Robbins P.D., et al. Vascular gene transfer of the human inducible nitric oxide synthase: characterization of activity and effects of myointimal hyperplasia. Mol. Med. 2:1996;211-215
77. Tulis D.A., Durante W., Liu X., et al. Adenovirus-mediated heme oxygenase-1 gene delivery inhibits injury-induced vascular neointima formation. Circulation. 104:2001;2710-2715
78. Laukkanen M.O., Kivela A., Rissane T., et al. Adenovirus-mediated extracellular superoxide dismutase gene therapy reduces neointima formation in balloon-denuded rabbit aorta. Circulation. 106:2002;1999-2003
79. Mann M.J., Gibbons G.H., Kernoff R.S., et al. Genetic engineering of vein grafts resistant to atherosclerosis. Proc. Natl. Acad. Sci. USA. 92(10):1995;4502-4506
80. Mann M.J., Gibbons G.H., Tsao P.S., et al. Cell cycle inhibition preserves endothelial function in genetically engineered rabbit vein grafts. J. Clin. Invest. 99(6):1997;1295-1301
81. Morishita R., Gibbons G.H., Ellison K.E., et al. A gene therapy strategy using a transcription factor decoy of the E2F binding site inhibits smooth muscle proliferation in vivo. Proc. Natl. Acad. Sci. 92:1995;5855-5859
82. Mann M.J., Whittemore A.D., Donaldson M.C., et al. Ex-vivo gene therapy of human vascular bypass grafts with E2F decoy: the PREVENT single-centre, randomized, controlled trial. Lancet. 354:1999;1493-1498
83. McCarthy M. Molecular decoy may keep bypass grafts open. Lancet. 358:2001;1703
84. Wilson J.M., Birinyi L.K., Salomon R.N., et al. Implantation of vascular grafts lined with genetically modified endothelial cells. Science. 244:1989;1344-1346
85. Dichek D.A., Neville R.F., Zwiebel J.A., et al. Seeding of intravascular stents with genetically engineered endothelial cells. Circulation. 80:1989;1347-1353
86. Parikh S.A., Edelman E.R. Endothelial cell delivery for cardiovascular therapy. Adv. Drug Del. Res. 42:2000;139-161
87. Nerem R.M., Seliktar D. Vascular tissue engineering. Ann. Rev. Biomed. Eng. 3:2001;225-243
88. Nugent H.M., Edelman E.R. Tissue engineering therapy for cardiovascular disease. Circ. Res. 92:2003;1068-1078
89. Asahara T., Masuda H., Takahashi T., et al. Bone marrow origin of endothelial progenitor cells responsible for postnatal vasculogenesis in physiological and pathological neovascularization. Circ. Res. 85:1999;221-228
90. Shintani S., Murohara T., Ikeda H., et al. Mobilization of endothelial progenitor cells in patients with acute myocardial infarction. Circulation. 103:2001;2776-2779
91. Takahashi T., Kalka C., Masuda H., et al. Ischemia- and cytokine-induced mobilization of bone-marrow-derived endothelial progenitor cells for neovascularization. Nat. Med. 5:1999;434-438
92. Kocher A.A., Schuster M.D., Szabolcs M.J., et al. Neovascularization of ischemic myocardium by human bone-marrow-derived angioblasts prevents cardiomyocyte apoptosis, reduces remodeling and improves cardiac function. Nat. Med. 7:2001;430-436
93. Hristov M., Erl W., Weber P.C. Endothelial progenitor cells: mobilization, differentiation, and homing. Arterioscler Thromb. Vasc. Biol. 23:2003;1185-1190
94. Nugent H.M., Rogers C., Edelman E.R. Endothelial implants inhibit intimal hyperplasia after porcine angioplasty. Circ. Res. 84:1999;384-391
95. Shirota T., Yasui H., Shimokawa H., et al. Fabrication of endothelial progenitor cell (EPC)-seeded intravascular stent devices and in vitro endothelialization on hybrid vascular tissue. Biomaterials. 24:2003;2295-2302
96. Consigny P.M. Endothelial cell seeding on prosthetic surfaces. J. Long Term Eff. Med. Implants. 10:2000;79-95
97. Dichek D.A., Anderson J., Kelly A.B., et al. Enhanced in vivo antithrombotic effects of endothelial cells expressing recombinant plasminogen activators transduced with retroviral vectors. Circulation. 93:1996;301-309
98. Lundell A., Kelly A.B., Anderson J., et al. Reduction in vascular lesion formation by hirudin secreted from retrovirus-transduced confluent endothelial cells on vascular grafts in baboons. Circulation. 100:1999;2018-2024
99. Kong D., Melo L.G., Mangi A.A., et al. Enhanced inhibition of neointima hyperplasia by genetically engineered endothelial progenitor cells. Circulation. 109:2004;1767-1775
100. Conte M.S., Birinyi L.K., Miyata T., et al. Efficient repopulation of denuded rabbit arteries with autologous genetically modified endothelial cells. Circulation. 89:1994;2161-2169
101. Bhattacharya V., Shi Q., Ishida A., et al. Administration of granulocyte colony-stimulating factor enhances endothelialization and microvessel formation in small caliber synthetic vascular grafts. J. Vasc. Surg. 32:2000;116-123
102. Shi Q., Bhattacharya V., Hong-De Wu M., et al. Utilizing granulocyte colony-stimulating factor to enhance vascular graft endothelialization from circulating blood cells. Ann. Vasc. Surg. 16:2002;314-320
103. Kong D, Melo LG, Gnecchi M et al. Cytokine-induced mobilization of endothelial progenitor cells enhances repair of injured arteries. Circulation 2004 (in revision)
104. Walter D.H., Rittig K., Bahlmann F.H., et al. Statin therapy accelerates reendothelialization: a novel effect involving mobilization and incorporation of bone marrow-derived endothelial progenitor cells. Circulation. 105:2002;3017-3024
105. Werner N., Priller J., Laufs U., et al. Bone marrow-derived progenitor cells modulate vascular reendothelialization and neointimal formation. Effect of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibition. Arterioscler. Thromb. Vasc. Biol. 22:2002;1567-1572
106. Strehlow K., Werner N., Berweiler J., et al. Estrogen increases bone-marrow derived endothelial progenitor cell production and diminishes neointima formation. Circulation. 107:2003;3059-3065
107. Lefer D.J., Granger D.N. Oxidative stress and cardiac disease. Am. J. Med. 109:2000;315-323
108. Singal P.K., Khaper N., Palace V. The role of oxidative stress in the genesis of heart disease. Cardiovasc. Res. 40:1998;426-432
109. Melo L.G., Pachori A.S., Zhang L., et al. Preemptive gene therapy by AAV-mediated delivery of heme oxygenase-1 results in long-term normalization of left ventricular function and chamber dimensions. Circulation. 108(Suppl. IV):2003;IV-144
110. Agrawal R.S., Muangman S., Melo L.G., et al. Recombinant adeno-associated virus mediated antioxidant enzyme delivery as preventive gene therapy against ischaemia-reperfusion injury of the rat myocardium. Mol. Therapy. 3:2001;A837
111. Yoshida T., Watanabe M., Engelman D.T., et al. Transgenic mice overexpressing glutathione peroxidase are resistant to myocardial reperfusion injury. J. Mol. Cell Cardiol. 28:1996;1759-1767
112. Suzuki K., Sawa Y., Kaneda Y. In vivo gene transfer of heat shock protein 70 enhances myocardial tolerance to ischaemia-reperfusion injury in rat. J. Clin. Invest. 99:1997;1645-1650
113. Brauner R., Nonoyama M., Laks H., et al. Intracoronary adenovirus-mediated transfer of immunosuppressive cytokine genes prolongs allograft survival. J. Thorac. Cardiovasc. Surg. 114:1997;923-933
114. Yang Z., Cerniway R.J., Byford A.M. Cardiac overexpression of A1-adenosine receptor protects intact mice against myocardial infarction. Am. J. Physiol. 282:2002;H949-H955
115. Ueda H., Sawa Y., Matsumoto K., et al. Gene transfection of hepatocyte growth factor attenuates reperfusion injury in the heart. Ann. Thorac. Surg. 67:1999;1726-1731
116. Bagley J., Iacomini J. Gene therapy progress and prospects: gene therapy in organ transplantation. Gene Ther. 10:2003;605-611
117. Pachori A.S., Melo L.G., Zhang L. Potential for germ cell line transmission after intramyocardial gene delivery by adeno-associated virus. Biochem. Biophys. Res. Commun. 313:2004;528-533
118. 165 as sole therapy for myocardial ischemia. Circulation. 98:1998;2800-2804
119. Vale P.R., Losordo D.W., Milliken C.E., et al. Randomized, single-blind, placebo-controlled pilot study of catheter-based myocardial gene transfer for therapeutic angiogenesis using left ventricular electromechanical mapping in patients with chronic myocardial ischemia. Circulation. 103:2001;2138-2143
120. Losordo D.W., Vale P.R., Hendel R.C., et al. Phase 1/2 placebo-controlled, double-blind, dose escalating trial of myocardial vascular endothelial growth factor 2 gene transfer by catheter delivery in patients with chronic myocardial ischemia. Circulation. 105:2002;2012-2018
121. Tio R.A., Tkebuchava T., Scheuermann T.H., et al. Intramyocardial gene therapy with naked DNA encoding vascular endothelial growth factor improves collateral flow to ischemic myocardium. Hum. Gene Ther. 10:1999;2953-2960
122. Lee L.Y., Patel S.R., Hackett N.R., et al. Focal angiogen therapy using intramyocardial delivery of an adenovirus vector coding for vascular endothelial growth factor 121. Ann. Thorac. Surg. 69:2000;14-24
123. Kawamoto A., Gwon H.-C., Iwaguro H., et al. Therapeutic potential of ex vivo expanded endothelial progenitor cells for myocardial ischemia. Circulation. 103:2001;634-637
124. Shintani S., Murohara T., Ikeda H., et al. Augmentation of postnatal neovascularization with autologous bone marrow transplantation. Circulation. 103:2001;897-903
125. Kawamoto A., Tkebuchava T., Yamaguchi J.-I., et al. Intramyocardial transplantation of autologous endothelial progenitor cells for therapeutic neovascularization. Circulation. 107:2003;461-468
126. Kamihata H., Matusbara H., Nishiue T., et al. Improvement of collateral perfusion and regional function by implantation of peripheral blood mononuclear cells into ischemic hibernating myocardium. Arterioscler. Vasc. Biol. 22:2002;1804-1810
127. Kamihata H., Matsubara H., Nishiue T., et al. Implantation of bone marrow mononuclear cells into ischemic myocardium enhances collateral perfusion and regional function via side supply of angioblasts, angiogenic ligands, and cytokines. Circulation. 104:2001;1046-1052
128. Kobayashi T., Hamano K., Li T.S., et al. Enhancement of angiogenesis by the implantation of self bone marrow cells in a rat ischaemic heart model. J. Surg. Res. 89:2000;189-195
129. Fuchs S., Baffour R., Zhou Y.F., et al. Transendocardial delivery of autologous bone marrow enhances collateral perfusion and regional function in pigs with chronic experimental myocardial ischaemia. J. Am. Coll. Cardiol. 37:2001;1726-1732
130. Bashir R., Vale P.R., Isner J.M., et al. Angiogenic gene therapy: pre-clinical studies and phase I clinical data. Kidney Int. 61(Suppl. 1):2002;110-114
131. Grines C.L., Watkins M.W., Helmer G., et al. Angiogenic gene therapy (AGENT) trial in patients with stable angina pectoris. Circulation. 105:2002;1291-1297
132. Grines C.L., Watkins M.W., Mahmarian J., et al. A randomized double-blind placebo controlled trial of Ad5FGF-4 gene therapy and its effect on myocardial perfusion in patients with stable angina. J. Am. Coll. Cardiol. 42:2003;1339-1347
133. Lee R.J., Springer M.L., Blanco-Bose W.E., et al. VEGF gene delivery to the myocardium. Deleterious effect of upregulated expression. Circulation. 102:2000;898-901
134. Celleti F.L., Waugh J.M., Amabile P.G., et al. Vascular endothelial growth factor enhances atherosclerotic plaque progression. Nat. Med. 7:2001;425-429
135. Rebar E.J., Huang Y., Hickey R., et al. Induction of angiogenesis in a mouse model using engineered transcription factors. Nat. Med. 8:2002;1427-1432
136. Iwaguro H., Yamaguchi J., Kalka C., et al. Endothelial progenitor cell vascular endothelial growth factor gene transfer for vascular regeneration. Circulation. 105:2002;732-738
137. Orlic D., Kajstura J., Chimenti S., et al. Mobilized bone marrow cells repair the infarcted heart, improving function and survival. Proc. Natl. Acad. Sci. USA. 98:2001;10344-10349
138. Yamaguchi J., Kusano K., Masuo O., et al. Stromal cell-derived factor-1 effects on ex vivo expanded endothelial progenitor cell recruitment for ischaemic neovascularization. Circulation. 107:2003;1322-1328
139. Vasa M., Fichtlscherer S., Adler K., et al. Increase in circulating endothelial progenitor cells by statin therapy in patients with stable coronary artery disease. Circulation. 103:2001;2885-2890
140. Dimmeler S., Aicher A., Vasa M., et al. HMG-CoA reductase inhibitors (statins) increase endothelial progenitor cells via the PI3-kinase/Akt pathway. J. Clin. Invest. 108:2001;391-397
141. Llevadot J., Murasawa S., Kureishi Y., et al. HMG-CoA reductase inhibitor mobilizes bone marrow-derived endothelial progenitor cells. J. Clin. Invest. 108:2001;399-405
142. Stamm C., Westphal B., Kleine H.-D., et al. Autologous bone-marrow transplantation for myocardial regeneration. Lancet. 361:2003;45-46
143. Strauer B.E., Brehm M., Zeus T., et al. Repair of infarcted myocardium by autologous intracoronary mononuclear bone marrow cell transplantation in humans. Circulation. 106:2002;1913-1918
144. Assmus B., Schachlinger V., Teupe C., et al. Transplantation of progenitor cells and regeneration enhancement in acute myocardial infarction (TOPCARE-AMI). Circulation. 106:2002;3009-3017
145. Perin E.C., Dohmann H.F.R., Borojevic R., et al. Transendocardial, autologous bone marrow cell transplantation for severe, chronic ischaemic heart failure. Circulation. 107:2003;2294-2302
146. Tse H.-.F., Kwong Y.-L., Chan J.K.F., et al. Angiogenesis in ischaemic myocardium by intramyocardial autologous bone marrow mononuclear cell implantation. Lancet. 361:2003;47-49
147. Soonpaa M.H., Field L. Survey of studies examining mammalian cardiomyocyte DNA synthesis. Circ. Res. 83:1998;15-26
148. St John Sutton M.G., Sharpe N. Left ventricular remodeling after myocardial infarction. Pathophysiology and therapy. Circulation. 101:2000;2981-2988
149. Reinlib L., Field L. Cell transplantation as future therapy for cardiovascular disease? Circulation. 101:2000;e192-e197
150. Reffelmann T., Kloner R.A. Cellular cardiomyoplasty - cardiomyocytes, skeletal myoblasts, or stem cells for regenerating myocardium and treatment of heart failure. Cardiovasc. Res. 58:2003;358-368
151. Jiang Y., Jahagirdar B.N., Reinhardt R.L., et al. Pluripotency of mesenchymal stem cells derived from adult marrow. Nature. 418:2002;41-49
152. Makino S., Fukuda K., Miyoshi S., et al. Cardiomyocytes can be generated from marrow stromal cells in vitro. J. Clin. Invest. 103:1999;697-705
153. Toma C., Pittenger M.F., Cahill K.S., et al. Human mesenchymal stem cells differentiate to a cardiomyocyte phenotype in the adult murine heart. Circulation. 105:2002;93-98
154. Wang J.S., Shum-Tim D., Chedrawy E., et al. The coronary delivery of marrow stromal cells for myocardial regeneration. Pathophysiological and therapeutic implications. J. Thorac. Cardiovasc. Surg. 122:2001;699-705
155. Beltrami A.P., Barlucchi L., Torella D., et al. Adult cardiac stem cells are multipotent and support myocardial regeneration. Cell. 114:2003;763-776
156. Oh H., Bradfute S.B., Gallardo T.D., et al. Cardiac progenitor cells from adult myocardium: homing, differentiation, and fusion after infarction. Proc. Natl. Acad. Sci. USA. 100:2003;12313-12318
157. Urbanek K., Quini F., Tasca G., et al. Intense myocyte formation from cardiac stem cells in human cardiac hypertrophy. Proc. Natl. Acad. Sci. USA. 100:2003;10440-10445